FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy

DEALS: GSK, Targacept ink $1.5B pain deal


GSK, Targacept ink $1.5B pain deal


DEALS

WHO

WITH

WHAT

SCOOP

GSK

Targacept

$1.5B deal

GSK and Targacept have inked a discovery, development and commercialization deal for therapeutics that target specified neuronal nicotinic receptors.

Meda

MedPointe

$800M buyout

Meda said that MedPointe's products, which focus on the areas of allergy, respiratory and pain, are a perfect fit for Meda's portfolio.

Genstar Capital

PRA International

$744 buyout

Genstar Capital has struck a deal to buy PRA International for $744 million, a premium of about 13 percent on PRA's stock price. PRA gets 50 days to solicit a better offer.

Merck

NovaCardia

$350M buyout

NovaCardia has a drug--KW-3902--in late-stage studies for congestive heart failure.

Pfizer Global R&D

Hydra Biosciences

$195M deal

Hydra stands to gain up to $195 million in up front and milestone payments the first product developed from the Transient Receptor Potential channel family.

SurModics

Brookwood Pharmaceuticals

$62M sale

The Southern Research Institute has sold Brookwood Pharmaceuticals to SurModics for $40M up front and up to $22M in milestones. Both SurModics and Brookwood specialize in drug delivery technologies.

Cell Therapeutics

Systems Medicine

$35M buyout

Systems Medicine is developing a genetically engineered drug called Brostallicin, which Cell Therapeutics believes is a "perfect fit" for its pipeline.

Antares Pharma

Jazz Pharmaceuticals

$16.5M development and licensing deal

The deal is for the development of therapeutics for an unnamed CNS disorder based on Antares' Advanced Transdermal Delivery system.

More stories about Merck   GlaxoSmithKline   Pfizer   heart disease   Deals   commercialization   targacept  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 9 + 41?
To combat spam, please solve the math question above.